Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma (Q34478021)

2 August 2017

title

Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma (English)

1 reference

2 August 2017

1 reference

Agnese Barnabei

7

0 references

Marialuisa Appetecchia

object named as

Marialuisa Appetecchia

1

0 references

Michele Gallucci

object named as

Michele Gallucci

10

0 references

Isabella Sperduti

object named as

Isabella Sperduti

9

0 references

author name string

Aurela Meçule

2

1 reference

2 August 2017

Giuseppe Pasimeni

3

1 reference

2 August 2017

Concetta V Iannucci

4

1 reference

2 August 2017

Piero De Carli

5

1 reference

2 August 2017

Roberto Baldelli

6

1 reference

2 August 2017

Giovanni Cigliana

8

1 reference

2 August 2017

publication date

17 December 2010

1 reference

Journal of Experimental & Clinical Cancer Research

2 August 2017

published in

1 reference

2 August 2017

volume

29

1 reference

2 August 2017

page(s)

166

1 reference

Creative Commons Attribution 2.0 Generic

2 August 2017

copyright license

start time

1 December 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Somatostatin receptors: from basic science to clinical approach. Unlabeled somatostatin analogues-1: Prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Neuroendocrine pathogenesis in adenocarcinoma of the prostate

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Serum chromogranin-A in advanced prostate cancer

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Elevated levels of serum secretoneurin in patients with therapy resistant carcinoma of the prostate.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3018395

Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment

27 October 2018

1 reference

12 December 2020

Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers

1 reference

12 December 2020

Neuroendocrine differentiation is not prognostic of failure after radical prostatectomy but correlates with tumor volume

1 reference

12 December 2020

Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin

1 reference

12 December 2020

Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer

1 reference

12 December 2020

Neuroendocrine serum tumour markers in hormone-resistant prostate cancer

1 reference

12 December 2020

Neuroendocrine differentiation in hormone refractory prostate cancer following androgen deprivation therapy

1 reference

12 December 2020

Histologic grade, clinical stage, and patient age in prostate cancer

1 reference

12 December 2020

Elevated Plasma Chromogranin-A Concentrations in Prostatic Carcinoma

1 reference

12 December 2020

Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinoma

1 reference

12 December 2020

Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors

1 reference

12 December 2020

The chromogranin-A (CgA) in prostate cancer

1 reference

12 December 2020

The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer

1 reference

12 December 2020

Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy

1 reference

12 December 2020

Neuroendocrine differentiation in prostate adenocarcinoma

1 reference

12 December 2020

Identifiers

DOI

10.1186/1756-9966-29-166

1 reference

Dimensions Publication ID

2 August 2017

0 references

1 reference

2 August 2017

1 reference